

In adult patients with existing coronary artery disease

# Add <sup>Pr</sup>MYINFLA™ to standard therapies for the reduction of atherothrombotic events

MYINFLA™ (colchicine extended-release tablets) is indicated for the reduction of atherothrombotic events in adult patients with existing coronary artery disease, in addition to standard therapies, including LDL-C-lowering and antithrombotic drug treatment.

## Recommended dosing†

0.5 mg once daily



**One pill,  
once daily**



**Administered  
orally**



## With or without food

Avoid taking grapefruit or grapefruit juice with MYINFLA™

<sup>Pr</sup>**myinfla™ ER**  
colchicine 0.5 mg  
extended-release tablets



\*Comparative clinical significance has not been established.

†Consult the Product Monograph for complete dosage and administration information.

In adult patients with existing coronary artery disease

## Add <sup>Pr</sup>MYINFLA™ to standard therapies for the reduction of atherothrombotic events

A convenient, once-daily, 0.5 mg low-dose add-on to standard therapies, including LDL-C-lowering and antithrombotic drug treatment

Use your phone's camera to scan the QR code to learn more about MYINFLA™.



### For more information

Please consult the Product Monograph at <https://pendopharm.com/wp-content/uploads/2022/05/MYINFLA-PM-EN.pdf?x32799> for important information relating to conditions of clinical use, contraindications, adverse reactions, warnings and precautions, drug interactions, and dosage and administration that has not been discussed in this piece. The Product Monograph is also available by contacting our Medical Information Department at 1-888-550-6060 or [medinfo@pendopharm.com](mailto:medinfo@pendopharm.com).

**Reference:** MYINFLA™ Product Monograph. PENDOPHARM, Division of Pharmascience Inc. August 20, 2021.

MYINFLA™ and the MYINFLA logo are trademarks owned by Finchley Research and Development Inc., used under licence by PENDOPHARM, a division of Pharmascience Inc. CAR230001E

Made in  
Canada



**myinfla™ ER**  
colchicine 0.5 mg  
extended-release tablets

